To develop more precise guidelines for managing diabetic vitreous hemorrhage and optimizing patient outcomes, future research should focus on well-designed clinical trials with standardized protocols-including clear documentation of anti-VEGF timing relative to surgery. The gene discussed is VEGFA; the disease is vitreous hemorrhage.